Cibus(CBUS)

Search documents
The U.S. Food and Drug Administration Completes Review of Cibus' Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed
Globenewswire· 2025-06-24 11:00
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that it has completed the U.S. Food and Drug Administration’s (FDA) Plant Biotechnology Consultation Program for its altered lignin alfalfa trait with the FDA notifying Cibus that it has no further questions concerning the use of altered lignin alfalfa in food or feed. To develop altered lignin alfalfa, C ...
Cibus and John Innes Centre Announce Ongoing Collaboration with Potential to Revolutionize Fertilizer Use in Farming
GlobeNewswire News Room· 2025-06-12 12:00
Core Insights - Cibus, in collaboration with the John Innes Centre (JIC), has discovered a genetic mutation that enhances nutrient uptake and reduces the need for artificial fertilizers [1][2][3] - The nutrient use efficiency (NUE) trait aims to improve crop yields while decreasing the reliance on nitrates and phosphates [1][4] - Cibus has successfully edited Canola plants with this mutation and is looking forward to further testing and validation [1][3] Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies for royalties [1][7] - The company utilizes proprietary high-throughput gene editing technology to create crop traits more efficiently than conventional breeding methods [7] - Cibus addresses critical productivity and sustainability challenges in agriculture, with an estimated global economic loss of approximately $300 billion annually due to diseases and pests [7] Research and Development - The collaboration with JIC aims to translate their discovery into a trait that enhances plant-microbe interactions, thereby boosting nutrient uptake [2][3] - The NUE trait is expected to lead to more productive and sustainable crops, allowing farmers to use less fertilizer while maintaining yields [3][4] - JIC's research highlights the inefficiency of plants in nutrient absorption, with only about one-third of applied fertilizer typically absorbed [3]
Cibus, Inc. Announces Closing of $27.5 Million Public Offering
Globenewswire· 2025-06-10 00:22
Core Insights - Cibus, Inc. has successfully closed a public offering of 15,714,285 shares of Class A Common Stock at a price of $1.75 per share, raising gross proceeds of $27.5 million [1][2] Company Overview - Cibus is a leading agricultural biotechnology company focused on developing plant traits through proprietary gene editing technologies, addressing productivity and sustainability challenges for farmers [6] - The company is not a seed company but a technology company that licenses developed crop traits to seed companies in exchange for royalties on seed sales [6] Use of Proceeds - The net proceeds from the offering will be utilized for the development of weed management productivity traits in rice, as well as for working capital and general corporate purposes [2] Offering Details - The offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission, with A.G.P./Alliance Global Partners acting as the sole placement agent [3][4]
USDA Designates Cibus' Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA's Biotechnology Regulations
GlobeNewswire News Room· 2025-06-06 13:26
Core Insights - Cibus, Inc. has received a "not regulated" designation from the USDA for its herbicide tolerance trait (HT2) in Canola, which supports the company's ongoing product development in this critical crop [1][2] - The HT2 trait is part of Cibus' strategy to provide advanced tools for weed management, addressing the challenge of herbicide-resistant weeds [2][3] - Cibus has a total of seventeen traits designated as not regulated, reflecting its successful regulatory progress and development pace [2] Company Overview - Cibus is a leader in gene-edited productivity traits aimed at addressing significant agricultural challenges, including diseases and pests, which cost the global economy approximately $300 billion annually [4] - The company focuses on developing productivity traits for major row crops and utilizes proprietary high-throughput gene editing technology to expedite the development process [4] Market Implications - The HT2 trait aims to enhance agricultural productivity and sustainability by improving weed management efficiency, which is crucial for crops like Canola and Soybean [3] - Cibus' advancements in herbicide tolerance traits are expected to benefit growers by increasing profitability and yield protection [3]
Cibus, Inc. Announces Pricing of $27.5 Million Public Offering
Globenewswire· 2025-06-05 12:30
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company" or "Cibus"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of its previously announced public offering of 15,714,285 shares of its Class A Common Stock, at a purchase price of $1.75 per share, including to institutional and strategic investors, as well as the Chairman of Cibus' ...
Cibus, Inc. Announces Proposed Public Offering
Globenewswire· 2025-06-04 20:19
Core Viewpoint - Cibus, Inc. plans to offer shares of its Class A common stock in a public offering, with the Chairman expressing interest in purchasing up to $10 million of shares [1][2]. Group 1: Offering Details - The offering will be conducted by Cibus and is subject to market conditions, with no assurance on the completion or terms of the offering [1]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [2]. - The securities will be offered under an effective shelf registration statement filed with the SEC [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund the development of weed management productivity traits in rice and for general corporate purposes [2]. Group 3: Company Overview - Cibus is a leader in gene-edited productivity traits aimed at addressing significant agricultural challenges, with an estimated global economic cost of $300 billion annually due to diseases and pests [5]. - The company focuses on developing crop traits using proprietary gene editing technology, which is faster and more cost-effective than traditional breeding methods [5].
Cibus Provides Webcast of BofA Securities AgTech Virtual Conference Fireside Chat
Globenewswire· 2025-05-27 11:00
Group 1 - Cibus, Inc. is a leading agricultural biotechnology company focused on developing plant traits through proprietary gene editing technologies [1][3] - The company participated in the BofA Securities 2025 AgTech Virtual Conference, discussing its gene editing platform and productivity trait pipeline [2] - Cibus addresses significant agricultural challenges, with the United Nations estimating that diseases and pests cost the global economy approximately $300 billion annually [3] Group 2 - Cibus is not a seed company but a technology company that licenses traits to seed companies in exchange for royalties [3] - The company has a pipeline of five productivity traits, focusing on weed management in rice, pod shatter reduction, and disease resistance [3] - Cibus aims to develop and commercialize plant traits more efficiently and cost-effectively than conventional breeding methods [3]
Cibus (CBUS) Conference Transcript
2025-05-21 21:40
Summary of Cibus (CBUS) Conference Call - May 21, 2025 Company Overview - **Company Name**: Cibus (Ticker: CBUS) - **Industry**: Agricultural Biotechnology - **Focus**: Development of gene-edited crop traits in canola, rice, and soy using a rapid trait development system - **Current Rating**: Buy with a price target of $23.50 [1] Core Points and Arguments Gene Editing vs. GMO - **Definition**: Gene editing involves making precise changes to an organism's DNA, while GMOs involve transferring genes from one organism to another [3][4] - **Regulatory Recognition**: Global regulators have acknowledged that gene-edited crops are indistinguishable from natural occurrences, leading to recent approvals in various countries, including Ecuador and the EU [6] Rapid Trait Development System (RTDS) - **Technology**: Utilizes a gene repair oligonucleotide to make precise edits at the single-cell level, allowing for multiple changes within genes and across genomes [7][8] - **Speed Advantage**: Traditional plant breeding can take 10-30 years; Cibus aims to deliver new traits within 12 months, significantly improving time-to-market [9][11] Revenue Model - **Pre-Revenue Status**: Currently, Cibus is a pre-revenue company, planning to generate income through royalties from developed traits [12] - **Market Potential**: Traits developed for major crops like soy, which covers over 250 million acres in North and South America, can lead to substantial royalty income [13] - **Royalty Estimates**: Expected royalties of $10 to $15 per acre for traits related to weed management, with potential for significant revenue as traits are adopted [14][15] Developed and Developing Traits - **Current Traits**: - **Rice**: Two herbicide-tolerant traits for efficient weed management [20][21] - **Canola**: Pod shatter reduction trait to preserve yield during harvest [22] - **Future Traits**: Advanced traits in development include additional herbicide tolerance and disease tolerance for canola and soy [23][24] Farmer Value Proposition - **Cost Reduction**: Traits can reduce input costs for farmers, improving profit margins by decreasing the need for herbicides and other inputs [25][26] - **Market Dynamics**: Farmers are willing to pay a premium for traits that enhance productivity and reduce operational costs [27] Timeline for Revenue Generation - **Projected Start**: Traits expected to be planted and royalties to begin flowing in 2027, with a gradual increase through 2029 [28][29] Near-Term Catalysts - **Customer Announcements**: New customer acquisitions in the rice portfolio and advancements in field trials for advanced traits [30][31] - **Wheat Platform**: Expansion into wheat traits is also being explored [31] Bio Fragrance Business - **Overview**: Cibus has discovered a yeast that produces oil, which can be used to create bio fragrances for consumer packaged goods (CPG) companies [32][33] - **Revenue Potential**: Expected nominal revenues in 2025, with significant growth potential in the tens of millions of dollars annually [34] Key Drivers for Business Growth - **Predictability and Speed**: Ability to deliver traits within 12 months is a significant competitive advantage [36] - **Regulatory Environment**: Harmonization of regulations globally opens up markets, allowing Cibus to operate similarly to conventional breeding programs [36][37] Other Important Content - **Market Size**: Major crops involved cover over 500 million acres, indicating a vast market opportunity for Cibus [36] - **Investor Interest**: Recent press releases have generated significant interest from prospective partners and customers [36] This summary encapsulates the key points discussed during the Cibus conference call, highlighting the company's innovative approach to agricultural biotechnology and its potential for future growth.
Cibus to Participate in Alliance Global Partner's Annual Virtual Healthcare Company Showcase
GlobeNewswire News Room· 2025-05-19 20:05
Group 1 - Cibus, Inc. is a leading agricultural biotechnology company focused on gene editing technologies to develop specific traits in seeds [1][3] - The company will present its advancements in gene-editing technology, regulatory developments, and commercialization strategy at the AGP Annual Virtual Healthcare Company Showcase [2][3] - Cibus addresses significant productivity and sustainability challenges for farmers, with an estimated global economic cost of $300 billion annually due to diseases and pests [3] Group 2 - Cibus operates as a technology company rather than a seed company, licensing traits to seed companies in exchange for royalties [3] - The company has a pipeline of five productivity traits, focusing on weed management in rice, pod shatter reduction, and disease resistance [3] - Cibus aims to develop and commercialize plant traits more efficiently and cost-effectively than conventional breeding methods [3]
Cibus (CBUS) Reports Q1 Loss, Misses Revenue Estimates
ZACKS· 2025-05-08 23:25
Group 1: Earnings Performance - Cibus reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.70, but an improvement from a loss of $1.12 per share a year ago, indicating a year-over-year improvement [1] - The company posted revenues of $1.03 million for the quarter, missing the Zacks Consensus Estimate by 12.37%, but showing an increase from $0.55 million in the same quarter last year [2] - Over the last four quarters, Cibus has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - Cibus shares have declined approximately 10.1% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the next quarter is -$0.68 on revenues of $1.2 million, and for the current fiscal year, it is -$2.66 on revenues of $9.93 million [7] Group 3: Industry Context - The Agriculture - Operations industry, to which Cibus belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - Another company in the same industry, Bioceres Crop, is expected to report a quarterly loss of $0.10 per share, reflecting a significant year-over-year decline [9]